Shingles Vaccine Market is Anticipated to Grow US$ 10.30 Bn By 2030

The global Shingles Vaccine market size is expected to reach USD  10.30  billion by 2030 and is expected to expand at a CAGR of 11.9% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38697

Growth Factors

 Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

By Product Analysis

Shingrix held the highest share of more than 91.0% in 2020 owing to the high efficacy of the vaccine with no serious events associated with it. Moreover, Shingrix is expected to grow at the highest rateover the forecast period. The growth of the segment can be attributed to the increasing awareness regarding the disease and approval of Shingrix vaccines in various regions.

SKYZoster is expected to grow at a significant CAGR over the forecast period owing to the recommendation of SKYZoster in South Korea, cost-effectiveness compared to Zostavax, and inclusion in immunization programs of some provinces in South Korea.

By Vaccine Type Analysis

The recombinant vaccine segment led the largest share of over 91.0% in 2020 owing to the high adoption of Shingrix in North America and the European region and the high efficacy of the recombinant vaccine to prevent disease in the adult population.

The live attenuated vaccine segment is expected to grow over the forecast period owing to the rising awareness regarding the disease and increasing adoption of vaccination in developing countries.

By Regional Analysis

North America grabbed the highest share of over 81.0% in 2020. The presence of major players in North America, favorable reimbursement policies, and high vaccine uptake are major factors driving the regional market. Vaccine uptake in the U.S. is around 35% and is more than 20% of the eligible population in Canada.

Asia Pacific is expected to expand at the fastest growth rate over the forecast period due to the increasing disposable income in the region, improvement in the healthcare policies, and a large population base having a high risk of developing the disease. 

Key Players

• GlaxoSmithKline plc.
• Merck & Co., Inc.
• SK chemicals
• Green Cross Corp
• Geneone Life Science
• Vaccitech
• CanSinoBIO

Market Segmentation

• By Product
  • Shingrix
  • Zostavax
  • SKYZoster
• By Vaccine Type
  • Recombinant Vaccine
  • Live Attenuated Vaccine
• Regional
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38697

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Shingles Vaccine Market, By Product

7.1.  Shingles Vaccine Market, by Product, 2021-2030

7.1.1.    Shingrix

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Zostavax

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    SKYZoster

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Shingles Vaccine Market, By Vaccine Type

8.1.  Shingles Vaccine Market, by Vaccine Type, 2021-2030

8.1.1.    Recombinant Vaccine

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Live Attenuated Vaccine

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Shingles Vaccine Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Product (2017-2030)

9.1.2.    Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Product (2017-2030)

9.2.2.    Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Product (2017-2030)

9.3.2.    Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Product (2017-2030)

9.4.2.    Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Product (2017-2030)

9.5.2.    Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Vaccine Type (2017-2030)

Chapter 10.  Company Profiles

10.1.              GlaxoSmithKline plc.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Merck & Co., Inc.

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              SK chemicals

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Green Cross Corp

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Geneone Life Science

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Vaccitech

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              CanSinoBIO

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38697

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com